Status:

WITHDRAWN

Early Alirocumab to Reduce LDL-C in Myocardial Infarction

Lead Sponsor:

Imperial College London

Collaborating Sponsors:

Regeneron Pharmaceuticals

Baim Institute for Clinical Research

Conditions:

Myocardial Infarction

Dyslipidemias

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The EARLY trial is a phase IV, investigator initiated, international, multicentre study that will investigate if early use of alirocumab 150mg plus atorvastatin 80mg (enhanced care) will have a greate...

Detailed Description

Patients with Acute Coronary Syndrome (ACS), which includes myocardial infarction, are at high risk of recurrent ischaemic events (e.g. heart attacks), and death. The current standard treatment includ...

Eligibility Criteria

Inclusion

  • Males or females aged 18 years or above
  • Admitted to hospital for ST-Segment Elevation MI (STEMI) or non-ST-Segment Elevation MI (NSTEMI) (proven by electrocardiogram (ECG) or biomarker evidence of MI)
  • Statin naïve prior to MI
  • Local LDL-C measurement available within 24 hrs of chest pain with no more than 1 dose of statin
  • Ability and willingness to give written informed consent and to comply with the requirements of the study

Exclusion

  • No ECG or biomarker evidence of MI
  • Received more than one dose of statin during the index event prior to randomisation
  • Contraindication to atorvastatin 80mg
  • Contraindication to ezetimibe
  • Contraindication to alirocumab
  • Unwillingness or inability to comply with study requirements, particularly with respect to laboratory tests, specifically blood draws 24 and 48 hours after randomisation, and subsequent clinic visits
  • New York Heart Association (NYHA) Class IV Heart Failure
  • Unstable arrhythmia
  • Subjects who in the opinion of investigator have a life expectancy of \< 9 weeks
  • Women of child bearing age who are not using at least 2 methods of contraception
  • Pregnant or breastfeeding.

Key Trial Info

Start Date :

January 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2021

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT03750760

Start Date

January 1 2020

End Date

December 1 2021

Last Update

June 13 2019

Active Locations (17)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (17 locations)

1

Royal Devon & Exeter Hospital

Exeter, Devon, United Kingdom, EX2 5DW

2

The Royal Bournemouth General Hospital

Bournemouth, Dorset, United Kingdom, BH7 7DW

3

East Sussex Healthcare NHS Trust

Saint Leonards-on-Sea, East Sussex, United Kingdom, TN37 7PT

4

Basildon Hospital

Basildon, Essex, United Kingdom, SS16 5NL